Association of Cerebrovascular Reactivity With 1-Year Imaging and Clinical Outcomes in Small Vessel Disease: An Observational Cohort Study.

Autor: Sleight E; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Stringer MS; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Clancy U; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Arteaga-Reyes C; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Jaime Garcia D; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Jochems ACC; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Wiseman S; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Valdes Hernandez M; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Chappell FM; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Doubal FN; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Marshall I; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Thrippleton MJ; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom., Wardlaw JM; From the Centre for Clinical Brain Sciences (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.) and UK Dementia Research Institute (E.S., M.S.S., U.C., C.A.-R., D.J.G., A.C.C.J., S.W., M.V.H., F.M.C., F.N.D., I.M., M.T., J.M.W.), University of Edinburgh, United Kingdom. Michael Thrippleton and Joanna Wardlaw are currently at Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, United Kingdom.
Jazyk: angličtina
Zdroj: Neurology [Neurology] 2024 Dec 10; Vol. 103 (11), pp. e210008. Date of Electronic Publication: 2024 Nov 05.
DOI: 10.1212/WNL.0000000000210008
Abstrakt: Background and Objectives: In patients with cerebral small vessel disease (SVD), impaired cerebrovascular reactivity (CVR) is related to worse concurrent SVD burden, but less is known about cerebrovascular reactivity and long-term SVD lesion progression and clinical outcomes. We investigated associations between cerebrovascular reactivity and 1-year progression of SVD features and clinical outcomes.
Methods: Between 2018 and 2021, we recruited patients from the Edinburgh/Lothian stroke services presenting with minor ischemic stroke and SVD features as part of the Mild Stroke Study 3, a prospective observational cohort study (ISRCTN 12113543). We acquired 3T brain MRI at baseline and 1 year. At baseline, we measured cerebrovascular reactivity to 6% inhaled CO 2 in subcortical gray matter, normal-appearing white matter, and white matter hyperintensities (WMH). At baseline and 1 year, we quantified SVD MRI features, incident infarcts, assessed stroke severity (NIH Stroke Scale), recurrent stroke, functional outcome (modified Rankin Scale), and cognition (Montreal Cognitive Assessment). We performed linear and logistic regressions adjusted for age, sex, and vascular risk factors, reporting the regression coefficients and odds ratios with 95% CIs.
Results: We recruited 208 patients of whom 163 (mean age and SD: 65.8 ± 11.2 years, 32% female) had adequate baseline CVR and completed the follow-up structural MRI. The median increase in WMH volume was 0.32 mL with (Q1, Q3) = (-0.48, 1.78) mL; 29% had a recurrent stroke or incident infarct on MRI. At 1 year, patients with lower baseline cerebrovascular reactivity in normal-appearing tissues had increased WMH (regression coefficient: B = -1.14 [-2.13, -0.14] log 10 (%ICV) per %/mm Hg) and perivascular space volumes (B = -1.90 [-3.21, -0.60] log 10 (%ROIV) per %/mm Hg), with a similar trend in WMH. CVR was not associated with clinical outcomes at 1 year.
Discussion: Lower baseline cerebrovascular reactivity predicted an increase in WMH and perivascular space volumes after 1 year. CVR should be considered in SVD future research and intervention studies.
Databáze: MEDLINE
Externí odkaz: